· Updated · Venture Capital Tracker · investment-strategies · 3 min read
Philadelphia Startups and VC Firms in 2026: dbt Labs, Crossbeam, Penn Cell Therapy
Philadelphia venture map in 2026 — dbt Labs, Crossbeam, Timbucktoo, Tmunity’s Penn CAR-T exit, Wealthmore, and national software/biotech /fund/ shortlists.
Philadelphia’s venture map in our directory is software scale (dbt Labs, Crossbeam) plus Penn Medicine cell-therapy history (Tmunity) — not a full University City census and not a local multi-stage HQ market.
This page maps the companies we actually profile.
City hub: /vc/philadelphia · All cities: /cities · Fund directory: /directory
What Philadelphia is (and is not)
| Philadelphia is… | Philadelphia is not… |
|---|---|
| Home to dbt Labs and Crossbeam as Philly HQ software anchors | A Boston-style biotech GP wall |
| Penn CAR-T proof via Tmunity’s exit path | First Round as a current Philly HQ fund (SF in our JSON) |
| Thin but real software + cell-therapy coverage | A padded University City name dump |
Startups we cover in Philadelphia
| Company | What they do | Stage / status | Notable capital | Profile |
|---|---|---|---|---|
| dbt Labs | Analytics engineering platform — dbt transforms warehouse data into tested metrics layers. | Growth | Andreessen Horowitz, Sequoia Capital, Coatue | /startup/dbt-labs |
| Crossbeam | Partner ecosystem platform for secure account mapping and B2B co-selling. | Growth | Andreessen Horowitz, Redpoint Ventures, FirstMark Capital | /startup/crossbeam |
| Timbucktoo | Art-tech platform using AI and blockchain for digital certificates of authenticity, insurance, and royalty tracking. | Seed | Andreessen Horowitz | /startup/timbucktoo |
| Tmunity Therapeutics | T-cell immunotherapy biotech (acquired by Instil Bio 2022). | Acquired | Andreessen Horowitz | /startup/tmunity-therapeutics |
| Wealthmore | Digital wealth management app pairing expert advisors with AI for everyday investors. | Pre Seed | Andreessen Horowitz | /startup/wealthmore |
Why these names matter
dbt Labs — dbt made ‘analytics engineering’ a discipline; its metrics layer is the foundation enterprises use before layering AI on trusted data.
Crossbeam — Network-effect B2B partnerships data layer — a16z led the $76M Series C as ecosystem-led sales became standard GTM for SaaS.
Timbucktoo — Philadelphia-based Timbucktoo treats art like a managed asset — DCA tech for collectors and galleries — backed through a16z Talent x Opportunity Fall 2024 as provenance friction keeps art illiquid.
Tmunity Therapeutics — Tmunity carried Penn cell-therapy science toward clinic — a16z bio bet consolidated when Instil Bio bought the platform for solid-tumor CAR-T expansion.
Wealthmore — Founder built for users like her grandmother — a16z TxO and Emmeline-led $1M pre-seed for accessible advisory beyond high-net-worth minimums.
Local investors (Philadelphia HQ or program)
| Firm | Role | Stages | Profile |
|---|---|---|---|
| None matched | — | — | No local HQ /fund/ rows yet |
How to read this: No Philadelphia HQ /fund/ matches. First Round’s historical Philly story is not a current HQ match (San Francisco in our JSON). BioAdvance-class seed is a gap.
National capital Philadelphia founders still need
Local funds rarely replace a coastal or specialist Series A. Pitch these directory firms by thesis, not geography:
| Firm | Why founders care | Profile |
|---|---|---|
| Andreessen Horowitz | Software + Bio (multiple Philly-linked caps) | /fund/andreessen-horowitz |
| Sequoia Capital | Growth software (dbt) | /fund/sequoia |
| Redpoint Ventures | Crossbeam Series B pattern | /fund/redpoint-ventures |
| Kleiner Perkins | Tmunity syndicate | /fund/kleiner-perkins |
| Define Ventures | Digital health specialist | /fund/define-ventures |
| F-Prime Capital | Life sciences / health | /fund/f-prime-capital |
Philly formation vs national software/biotech — what differs
| Local / university seed (offline) | National Series A+ | |
|---|---|---|
| Best for | First checks, Penn/CHOP intros | Category software or cell/gene rounds |
| Check shape | University seed / BioAdvance-class (gaps) | a16z / Sequoia / specialist priced rounds |
| Underwrite | Philly talent + early customers | National category leadership |
| Mistake | Calling First Round a Philly HQ fund in our data | Treating Tmunity as an active pitch peer (acquired) |
Worked example (illustrative)
Setup: A Philadelphia B2B SaaS startup raises a $10M Series A with coastal participation while keeping HQ in Philly (Crossbeam-class path).
Move: They raise a $75M+ Series C from a16z-class growth capital as ecosystem or data network effects clear.
Punch: Philly HQ was compatible with coastal multi-stage ownership — dbt and Crossbeam are the existence proofs.
When Philadelphia is the wrong capital market
- You need living University City cell/gene peers beyond Tmunity — mostly gaps today.
- You treat First Round as Philadelphia HQ in our directory — it is not.
- You invent BioAdvance
/fund/pages we have not shipped. - You pad Philly coverage with NYC companies.
How to use this page
- Read dbt Labs, Crossbeam, Timbucktoo, Tmunity, Wealthmore.
- National capital: table above + /directory.
- Live hub: /vc/philadelphia.
- East Coast context: East Coast VC firms 2026.
Related reading
Sources
- Startup profiles: dbt-labs, crossbeam, timbucktoo, tmunity-therapeutics, wealthmore
- dbt Series D (Feb 2022, $222M at $4.2B); Crossbeam Series C (2021, $76M, a16z)
- philadelphia
- pennsylvania
- venture-capital
- +3 more
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
